Clinical Trial Update: Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic [Phase 3]

View source ↗

Summary

Phase 3 study evaluating VPM1002 for reducing hospital admissions and severe respiratory infectious diseases in elderly during the COVID-19 pandemic; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infection of the Respiratory Tract
• Respiratory Tract Infection

Drugs mentioned

• VPM1002 (recombinant Bacillus Calmette-Guérin vaccine (rBCG))

Snippet

Sponsor: Serum Life Science Europe GmbH | Conditions: Infection, Respiratory Tract | Phase 3 | Status: COMPLETED